Labeling of Ready-to-Use Prescription Drug Injectables Subject of FDA Guidance

Recommendations on labeling of injectable prescription drug product information submitted in an NDA or certain BLAs is the subject of an FDA guidance on dose banding.
Source: Drug Industry Daily